➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Medtronic
Colorcon
AstraZeneca
Mallinckrodt

Last Updated: August 1, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,861,630


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,861,630
Title:1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment
Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl)]piperazine exhibits potent activity on SERT, 5-HT.sub.3 and 5-HT.sub.1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
Inventor(s): Faldt; Andre (Ishoj, DK), Lopez de Diego; Heidi (N.ae butted.rum, DK), Holm; Rene (Jyllinge, DK)
Assignee: H. Lundbeck A/S (Valby, DK)
Application Number:15/674,043
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,861,630
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,861,630

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-001 Sep 30, 2013 RX Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER ⤷  Try it Free
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-002 Sep 30, 2013 RX Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER ⤷  Try it Free
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-003 Sep 30, 2013 DISCN Yes No ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER ⤷  Try it Free
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes ⤷  Try it Free ⤷  Try it Free METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,861,630

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2006 00824Jun 16, 2006
Denmark2006 01223Sep 22, 2006
Denmark2006 01384Oct 25, 2006
Denmark2007 00427Mar 20, 2007

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Express Scripts
Colorcon
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.